Core Insights - Inspire Medical Systems, Inc. (INSP) reported a significant increase in earnings per share (EPS) for the fourth quarter of 2024, reaching $1.15, which is a 134.7% increase from the previous year's EPS of 49 cents, and exceeded the Zacks Consensus Estimate by 55.4% [1] - The full-year 2024 EPS was $1.75, compared to a loss of 72 cents per share in 2023, surpassing the Zacks Consensus Estimate by 31.6% [2] Revenue Performance - Inspire Medical's revenues for the fourth quarter were $239.7 million, reflecting a year-over-year increase of 24.5%, and slightly beating the Zacks Consensus Estimate by 0.04% [3] - For the full year 2024, revenues totaled $802.8 million, marking a 28.5% increase from 2023 [3] Geographic Revenue Breakdown - U.S. revenues for the fourth quarter amounted to $231.6 million, up 22% year-over-year [4] - International revenues reached $8.1 million, showing a remarkable year-over-year increase of 163% [5] Margin and Expense Analysis - Gross profit for the fourth quarter increased by 23.9% to $203.7 million, although the gross margin contracted by 44 basis points to 84.9% [6] - Selling, general, and administrative expenses rose by 14% year-over-year to $141.5 million, while research and development expenses decreased by 2.3% to $30.3 million [6] Operating Performance - Operating profit for the quarter was $31.9 million, a substantial increase of 242.9% from the prior year, with the operating margin expanding by 847 basis points to 13.3% [7] Financial Position - At the end of 2024, Inspire Medical had cash and cash equivalents and short-term investments totaling $445.5 million, down from $460.4 million at the end of 2023 [8] - Cumulative net cash provided by operating activities increased to $130.2 million from $24.7 million a year ago [8] Future Outlook - Inspire Medical has reiterated its revenue outlook for 2025, projecting revenues between $940 million and $955 million, which represents a growth of 17-19% from 2023 levels [10] - The company expects EPS for 2025 to be in the range of $2.10 to $2.20, compared to the Zacks Consensus Estimate of $2.03 [10] Strategic Developments - During the reported quarter, Inspire Medical activated 72 new U.S. centers, increasing the total to 1,435 centers providing Inspire therapy, and created 12 new U.S. sales territories, bringing the total to 335 [5] - The management highlighted positive early feedback from the Inspire V device and the full launch of the new Inspire SleepSync programming system in the U.S., which aims to enhance patient programming efficiency and data access [12]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $239.7 million, a 25% increase from $192.5 million in Q4 2023 [26] - Net income for Q4 2024 was $35.2 million, compared to $14.8 million in the prior year, representing diluted net income of $1.15 per share versus $0.49 per share in Q4 2023 [11][28] - For the full year 2024, revenue totaled $802.8 million, a 28% increase over $624.8 million in 2023, with net income of $53.5 million compared to a net loss of $21.2 million in 2023 [31] Business Line Data and Key Metrics Changes - U.S. revenue in Q4 2024 was $231.6 million, a 22% increase from $189.4 million in the prior year [26] - Revenue outside the U.S. was $8.1 million, a 163% increase year-over-year [26] - The company added 72 new U.S. centers in Q4 2024, bringing the total to 1,435 active U.S. centers [27] Market Data and Key Metrics Changes - The company continues to expand its market presence, with a focus on increasing patient access and therapy adoption [24] - The Inspire V neurostimulator received FDA approval, which is expected to enhance market penetration and patient outcomes [12] Company Strategy and Development Direction - The company aims to drive growth through the adoption of Inspire therapy, enhancing patient access, and increasing the capacity of provider partners [24] - Key strategies include adding advanced practice providers and certifying additional surgeons qualified to implant Inspire therapy [25] - The company plans to invest in medical education programs to improve awareness and adoption of Inspire therapy [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth strategy and the potential for long-term stakeholder value [25] - The company anticipates continued revenue growth in 2025, with guidance of $940 million to $955 million, representing a 17% to 19% increase year-over-year [32] - Management acknowledged the ongoing investigation by the Department of Justice but does not expect it to interfere with business operations [24][41] Other Important Information - The company generated $130 million in operating cash flow for the full year 2024, with total cash and investment balances reaching $517 million [29] - The Inspire V device is designed to reduce surgical complexity and improve patient outcomes, with positive early feedback from initial procedures [13][14] Q&A Session Summary Question: EPS guidance and DOJ CID - Management indicated that they do not expect to be profitable in Q1 but anticipate sequential improvement throughout the year [39] - Regarding the DOJ CID, management committed to cooperating with the investigation and emphasized their compliance programs [41][42] Question: Impact of digital scheduling on patient volume - Management reported significant advantages in patient appointment success using digital scheduling, leading to increased participation in the program [47][48] Question: Inspire V reimbursement and physician feedback - Management believes the Inspire V will not be a barrier to adoption, as it simplifies the procedure for ENT surgeons [52][54] Question: Revenue phasing and expenses for Inspire V launch - Management expects sequential revenue growth throughout the year, with continued investments in R&D and expansion of sales territories [62] Question: International revenue growth and interest income - Management indicated that international revenue is expected to remain a small percentage of total revenue, while interest income is projected at $20 million for the year [93][95] Question: Inventory build for Inspire V - Management confirmed that they are actively building inventory for Inspire V and have opened a new production line to support this [127][128] Question: Long-term center base outlook - Management expressed a commitment to consistent growth and expanding the center base over the next 3 to 5 years [148]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $239.7 million, a 25% increase from $192.5 million in Q4 2023 [26] - Net income for Q4 2024 was $35.2 million, compared to $14.8 million in the prior year, representing diluted net income of $1.15 per share versus $0.49 per share in Q4 2023 [11] - Full year 2024 revenue totaled $802.8 million, a 28% increase over $624.8 million in 2023 [30] - Full year diluted net income per share was $1.75 compared to a net loss of $0.72 per share in 2023 [31] Business Line Data and Key Metrics Changes - U.S. revenue in Q4 2024 was $231.6 million, a 22% increase from $189.4 million in the prior year [26] - Revenue outside the U.S. was $8.1 million, a 163% increase year-over-year [26] - Gross margin in Q4 2024 was 85% [27] - Adjusted EBITDA for Q4 2024 was $62.7 million, a 26% adjusted EBITDA margin compared to $33 million or a 17% margin in Q4 2023 [29] Market Data and Key Metrics Changes - The company added 72 new U.S. centers in Q4 2024, bringing the total to 1,435 active U.S. centers [27] - Revenue outside the U.S. for the full year 2024 was $31.8 million, a 71% year-over-year growth [30] Company Strategy and Development Direction - The company aims to enhance patient access and therapy outcomes through organizational changes and new leadership roles [9] - Key strategies include adding advanced practice providers, certifying additional surgeons, and driving the adoption of new digital tools [25] - The Inspire V neurostimulator is expected to simplify procedures and improve efficiency, with a full launch planned for 2025 [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full year 2025 revenue guidance of $940 million to $955 million, representing 17% to 19% growth year-over-year [11][32] - The company is committed to improving annual operating margins and expects sequential improvement throughout 2025 [39] - Management remains focused on ethical business practices amid a civil investigative demand from the Department of Justice [23][24] Other Important Information - The company generated $130 million in operating cash flow for the full year 2024, increasing total cash and investment balances to $517 million [29] - The Inspire V device incorporates respiratory sensing, reducing surgical complexity and costs [13] Q&A Session Summary Question: EPS guidance and DOJ CID - Management indicated that they do not expect to be profitable in Q1 but anticipate sequential improvement throughout the year [39][41] Question: Impact of automated scheduling on patient volume - Management reported significant advantages in patient appointment success using digital scheduling, leading to increased participation in the program [47][48] Question: Inspire V reimbursement and physician feedback - Management believes the Inspire V will not be a barrier for physicians and will actually encourage more cases due to reduced surgical time [52][54] Question: Revenue and expense phasing with Inspire V launch - Management expects sequential revenue growth throughout the year, with continued investments in R&D and expansion of sales territories [62] Question: International revenue growth and interest income - Management indicated that international revenue will continue to represent 3% to 4% of worldwide revenue, with interest income expected to be around $20 million for the year [94][95] Question: Inventory build for Inspire V - Management confirmed that they are actively building inventory for Inspire V and have opened a new production line to support this [127][129] Question: Long-term center base outlook - Management aims to continue growing the number of centers and expects to maintain a consistent growth trajectory over the next few years [148]

The sleep apnea specialist's fourth-quarter results surpassed expectations.Inspire Medical Systems (INSP -0.64%), known for its innovative devices that use neurostimulation to treat sleep apnea, announced impressive fourth-quarter results on Feb. 10. Earnings per share (EPS) came in at $1.15, well ahead of the $0.73 consensus estimate. Revenue climbed to $239.7 million, exceeding the forecast of $236 million. MetricQ4 2024Q4 2024 Analysts' EstimateQ4 2023% ChangeEPS (diluted)$1.15$0.73$0.49134.7%Revenue$239 ...

Core Insights - Inspire Medical Systems (INSP) reported revenue of $239.72 million for the quarter ended December 2024, marking a year-over-year increase of 24.5% and exceeding the Zacks Consensus Estimate of $239.62 million by 0.04% [1] - The company achieved an EPS of $1.15, significantly higher than the $0.49 reported a year ago, resulting in an EPS surprise of 55.41% compared to the consensus estimate of $0.74 [1] Financial Performance - Inspire's stock has returned -10% over the past month, contrasting with the Zacks S&P 500 composite's increase of 2.1% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3] Operational Metrics - Inspire opened 72 new U.S. Medical Centers, surpassing the average estimate of 59 by four analysts [4] - The total number of U.S. Medical Centers reached 1,435, slightly above the average estimate of 1,430 [4] - The company established 12 new U.S. sales territories, which is below the average estimate of 13 by three analysts [4] - The total number of U.S. sales territories stands at 335, marginally below the average estimate of 336 [4]

Inspire Medical Systems (INSP) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 55.41%. A quarter ago, it was expected that this maker of devices for treating obstructive sleep apnea would post earnings of $0.06 per share when it actually produced earnings of $0.60, delivering a surpri ...

Inspire Medical Systems (INSP) Q4 2024 Earnings Call February 10, 2025 05:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor RelationsTimothy Herbert - Founder, Chairman, CEO & PresidentRichard Buchholz - Chief Financial OfficerTravis Steed - Managing Director - Equity ResearchChris Pasquale - Partner - Medical Devices & SuppliesAnthony Petrone - Managing DirectorRichard Newitter - Managing DirectorJonathan Block - Managing DirectorMike Kratky - Senior Managing Director, Medical Devices a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2024. Recent Business Highlights and Full Year 2025 Guidance Generated revenue of $239.7 million for the fourth quarter of 2024, a 25% increase over the same quarter last ...

In its upcoming report, Inspire Medical Systems (INSP) is predicted by Wall Street analysts to post quarterly earnings of $0.74 per share, reflecting an increase of 51% compared to the same period last year. Revenues are forecasted to be $239.62 million, representing a year-over-year increase of 24.5%.The consensus EPS estimate for the quarter has been revised 23.3% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial ...